Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor
Author:
Funder
Kobe City Medical Center General Hospital
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference21 articles.
1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009
2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010
3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010
4. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial;Janne;J. Clin. Oncol.,2012
5. Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor;Chang;Tuberc. Respir. Dis.,2013
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases;Receptors;2024-04-05
2. A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms;Current Problems in Cancer: Case Reports;2024-03
3. Small Biopsy and Cytology of Pulmonary Neuroendocrine Neoplasms: Brief Overview of Classification, Immunohistochemistry, Molecular Profiles, and World Health Organization Updates;Advances in Anatomic Pathology;2022-09-02
4. Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature;International Journal of Cancer;2022-07-13
5. In‐depth molecular analysis of combined and co‐primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma;International Journal of Cancer;2021-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3